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Background:  Cystatin C levels reflects glomerular filtration rate and predict cardiovascular mortality and morbidity in coronary artery disease. Our 
aim was to determine the predictive power of cystatin C in patients with STEMI as well as in NSTE-ACS.
Methods:  Cystatin C measured at randomization in 16402 (of 18624 included) patients in the PLATO study (6638 STEMI and 9764 suspected 
NSTE-ACS) was evaluated as a predictor of the composite endpoint of cardiovascular death or myocardial infarction (MI) within one year. Cystatin 
C was evaluated as a continuous variable (logarithmized), as quartiles and dichotomized at optimal cutoff using the Integrated Discrimination 
Improvement (IDI) measure. Two Cox proportional hazards models were used: 1/ established traditional risk factors (e.g. age, gender, heart failure, 
diabetes, BMI, randomized treatment) and 2/ above mentioned and the addition of further risk markers e.g. NT-proBNP and CRP.
Results:  The median cystatin C value was 0.77 mg/L in the STEMI group and 0.86 mg/L in the NSTE-ACS group. The hazard ratios for the 
continuous models were derived per standard deviation 0.35 log(mg/L). The optimal cutoff was 1.09 mg/L. There was no significant cystatin C by 
type of ACS interaction (STEMI or NSTE-ACS).
STEMI NSTE-ACS
N HR (95% CI) N HR (95% CI)
Continuous model 1 6614 1.28 (1.18-1.39) 9729 1.28 (1.20-1.36)
Continuous model 2 5278 1.06 (0.96-1.16) 8053 1.11 (1.03-1.20)
Cutoff IDI model 1 6614 1.80 (1.48-2.18) 9729 1.64 (1.43-1.89)
Cutoff IDI model 2 5278 1.19 (0.95-1.49) 8053 1.23 (1.05-1.45)
Quartiles model 1
<0.68 2162 1885
0.68-0.83 1770 1.12 (0.88-1.44) 2342 0.95 (0.75-1.20)
0.83-1.01 1446 1.29 (1.00-1.65) 2699 1.26 (1.02-1.56)
≥1.01 1236 1.94 (1.53-2.45) 2803 1.73 (1.41-2.13)
Quartiles model 2
<0.68 1680 1520
0.68-0.83 1406 1.01 (0.77-1.33) 1916 0.95 (0.74-1.23)
0.83-1.01 1168 0.99 (0.75-1.31) 2286 1.15 (0.91-1.46)
≥1.01 1024 1.20 (0.92-1.57) 2331 1.29 (1.02-1.63)
Conclusions:  The cystatin C level contributes independently in predicting the risk of cardiovascular death or MI in NSTE-ACS and shows no 
interaction by type of ACS. Thereby cystatin C may be an additional tool for risk stratification in both STEMI and NSTE-ACS.
